A study to evaluate the safety and efficacy of the addition of a new drug (MK-3102) in patients with Type 2 Diabetes between the age of 18 and 44 years old, who are not taking any medications 1. To assess the effect of treatment with MK-3102 compared with placebo on A1C. 2. To assess the safety and tolerability of MK-3102.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of MK-0431 Monotherapy in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control Main objective : In patients with type 2 diabetes mellitus with inadequate glycemic control on diet and exercise: (1) After 24 weeks, to assess the effect of treatment with MK-0431 compared with plac...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10mg/20mg) compared to Rosuvastatin 10mg in patients with primary hypercholesterolemia and high cardiovascular risk and not adequately controlled with a prior statin treatment. (IN-CROSS) In patients with primary hypercholesterolemia and high cardiovascular risk treated with a statin and with elevated LDL-Cholesterol at baseline to assess the additional LDL-C percentage reduction by sw...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension To study the effects of losartan compared to placebo (nonhypertensives) or amlodipine (hypertensives) on reduction of proteinuria in children and adolescents up to 17 years of age with hypertension (i...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized Clinical Trial to Evaluate the Effects of High Dose Statin and Niacin Therapy on Excised Plaque Biomarkers in Patients Undergoing Carotid Endarterectomy (CEA) To determine whether 4 to 12 weeks of treatment with atorvastatin 80 mg/day + niacin ER 2 g/day compared to low dose atorvastatin 10 mg/day will result in a difference in the following endpoints: (1...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and End-Stage Renal Disease Who Are on Dialysis and Who Have Inadequate Glycemic Control After 54 weeks, to assess the effect (change from baseline) of sitagliptin on HbA1c; After 54 weeks, to assess the safety and tolerability of sitagliptin.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to evaluate the safety and efficacy of the addition of a new drug (MK-3102) in patients with Type 2 Diabetes who are also receiving Glimepiride and Metformin (1) After 24 weeks, to assess the effect of the addition of treatment with MK- 3102 compared with the addition of placebo on A1C. (2) To assess the safety and tolerability of MK 3102.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Immunotherapeutic treatment with Pembrolizumab (antibody) in patients with early stage non-small cell lung cancer Tratamiento inmunoterápico con Pembrolizumab (anticuerpo) en pacientes en estadios iniciales de cáncer pulmonar no microcítico To prospectively investigate whether adjuvant treatment with pembrolizumab after completion of radical surgery (lobectomy/pneumonectomy) with or without standard adjuvant chemotherapy for stage IB (T ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A clinical trial to test if the drug ertugliflozin is safe and effective when compared to glimepiride in patients with Type 2 Diabetes whose sugar levels are not well controlled by treatment with metaformin In subjects with T2DM and inadequate glycemic control on metformin: 1. After 52 weeks, to assess the A1C-lowering efficacy of the addition of ertugliflozin 15 mg q.d. compared with the addition of gl...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Ensayo clínico aleatorizado y controlado con producto de comparación activo en fase III para estudiar la seguridad y la eficacia de MK 0826/ertapenem y meropenem en pacientes con infecciones urinarias complicadas. A Phase III, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0826/Ertapenem and Meropenem in Patients with Complicated Urinary Tract Infections 1) To compare the efficacy of ertapenem with respect to the overall microbiological response assessment profile in the treatment of patients with serious (requiring hospitalization and treatment with ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune